Active substance
Levomepromazine
- US FDA 1
- UK MHRA 10
- NHS prices 6
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LEVOPROME | 20MG/ML | injectable · injection | IMMUNEX | Discontinued |
UK MHRA United Kingdom — marketing authorisations
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| LEVOMEPROMAZINE HYDROCHLORIDE 25MG/ML SOLUTION FOR INJECTION | PL 29831/0462 | WOCKHARDT UK LIMITED | POM |
| LEVOMEPROMAZINE MALEATE 25MG TABLETS | PL 20117/0337 | MORNINGSIDE HEALTHCARE LIMITED | POM |
| LEVOMEPROMAZINE MALEATE 25MG TABLETS | PL 56809/0016 | GALVANY PHARMA LIMITED | POM |
| LEVOMEPROMAZINE MALEATE 50MG TABLETS | PL 20117/0338 | MORNINGSIDE HEALTHCARE LIMITED | POM |
| LEVOMEPROMAZINE MALEATE 6MG TABLETS | PL 20117/0334 | MORNINGSIDE HEALTHCARE LIMITED | POM |
| LEVOROL 5 MG/ML ORAL SOLUTION | PLGB 56809/0001 | GALVANY PHARMA LIMITED | POM |
| LEVOROL 6.25 MG TABLETS | PL 56809/0015 | GALVANY PHARMA LIMITED | POM |
| NORPHEX 6MG TABLETS | PL 20117/0334 | MORNINGSIDE HEALTHCARE LIMITED | POM |
| NOZINAN 25MG TABLETS | PL 49718/0107 | NEURAXPHARM UK LIMITED | POM |
| NOZINAN 25MG/ML SOLUTION FOR INJECTION OR INFUSION | PL 49718/0106 | NEURAXPHARM UK LIMITED | POM |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Levomepromazine 25mg tablets | £33.65 | 84 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Levomepromazine 25mg/1ml solution for injection ampoules | £20.13 | 10 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Levomepromazine 50mg tablets | £34.00 | 84 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Levomepromazine 6.25mg tablets | £181.00 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Levomepromazine 6mg tablets | £247.20 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Levomepromazine hydrochloride 25mg/5ml oral solution sugar free | £175.00 | 100 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.